 |
|
|
|
|
 Future Technologies In Biologics Manufacturing -Transform Bioprocess Productivity And Over Come The Challenges Of Speed, Survival And Innovation
Leveraging Single Use Innovation To Overcome Challenges In Speed, Cost And Maintenance Times Whilst Remaining Flexible For Process & Manufacturing Requirements
Achieving Competitive Advantage And Worldwide Regulatory Compliance In Contract Manufacturing
Road Map into Achieving operational excellence through lean manufacturing
Leveraging Technology With Lean Principles To Overcome Challenges In Speed, Cost Resource, Productivity Whist In Line With Global Regulations, Achieve An Competitive Advantage And Manufacturing Supremacy.
Leveraging Innovation To Transform Bioprocess Productivity: Bridging The Gap Between Upstream Productivity & Down Stream Processes To Over Come Cost, Speed, Regulations & Efficiency Across The Whole Production
Taking a holistic, intergrated approach to disposable manufacturing
|
|
|
 |
|
 |
|
| |
 |
Morten Munk
Vice President, Co Founder
CMC Biopharmaceuticals
Its six founder managers incorporated CMC in March 2001. Prior to CMC, the founder team held senior management positions within the Novo Nordisk A/S and Novozymes A/S manufacturing and quality units. Core skills include fermentation, recovery, purification, analysis and control, quality assurance, Current Good Manufacturing Practice (cGMP) and regulatory matters, as well as facility management, process development, scale-up and technology development. |
|
 |
|
 |
Joe Zhou Ph.D
Director Process Development
Amgen Inc
Dr Joe X Zhou is Principal Scientist in the Process Development Department, Amgen Inc. Dr. Zhou's expertise is in non-cGMP and cGMP Protein/antibody therapeutics purification/production.
He is experienced in all aspects of process research, process optimisation, viral clearance, and characterization as well as laboratory set up and Project management. He has completed seven patent applications, five Process publications and three book chapters since joining Amgen In 2004, received many awards and spoken at many international conferences |
|
|
|
|
|
 |
Prof.M.Morbidelli
Director Chemical Bioengineering
ETH Zurich, Switzerland
Massimo Morbidelli, Prof. ETH, PhD, received his PhD in Chemical Engineering at the University of Notre Dame (USA) in 1986. After his first appointments as professor at the University of Cagliari (Italy) and Politecnico di Milano, he is since 1997 Professor at the Institute for Chemical and Bioengineering at ETH Zurich. Massimo Morbidelli is co-author of more than 300 papers, 11 international patents and four books.
He serves as a member of the Editorial Board of several international scientific journals and is a member of the Scientific Advisory Board of the Max-Planck Institute for Dynamics and Complex Technical Systems, Magdeburg, Germany. |
|
| |
|
|
|
 |
Mario Phillips
Managing Director
ATMI Life Sciences
Mario joined ATMI in 1999 with ATMI's acquisition of MST Analytics Inc, and was appointed as European Sales Manager for ATMI Analytical Systems. In October 2000 Mario moved to ATMI Packaging as global Sales and Marketing Manager. In August 2003 Mario was appointed General Manager for ATMI Packaging Solids Packaging business.
Early in 2004, upon the formation of ATMI Packaging Biopharma business unit, Mario was appointed Global Business Unit Manager-Biopharma. Before joining ATMI he was European Sales Manager with FPM Analytics, a Chicago based manufacturer of on-line wet chemical analyzers.He spent four years with Ankersmit Benelux, a European distributor for analytical equipment, where he held positions in sales. Mario started his career as Quality Assurance Manger with Amylum Belgium, an international sugar syrup company. Mario holds an engineering degree in biochemistry and has a postgraduate degree in marketing. |
|
|
|
|
|
 |
Kim Sandell
Director of Manufacturing
Pfizer Sweden
Kim Sandell joined Pfizer in Strängnäs, Sweden 1999. He holds a master degree in chemical engineering from Royal Institute of Technology Stockholm, Sweden. Kim is currently holding a position as project director for a new biotech plant under construction in Strängnäs. He is responsible for the end user representation and start-up activities for this new facility. Kim has held a range of position at the site starting as a process engineer moving into project lead and quality support to projects.
He then resumed responsibility for the manufacturing at the site until he joined the project team for the new facility. Strängnäs is a site focused in biotechnological API production with bacteria as expression systems. Staring up the new facility will also mean that two new processes for the API for Genotropin® and Somavert® will be transferred to the site this is also within Kim's responsibility. |
|
|
|
|
|
| |
|
| |
|
Read More 
